Compare Orion Office REIT Inc (ONL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs Recursion Pharmaceuticals Inc — how do they compare? Orion Office REIT Inc trades at $2.55 (market cap $151.74M), while Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 12.3× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.01% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ONL | RXRX | |
|---|---|---|
Market Cap | $151.74M | $1.86B |
Sector | Real Estate | Health |
52-Week High | $3.00 | $6.79 |
52-Week Low | $1.93 | $2.84 |
Enterprise Value | $568.67M | $1.38B |
Dividend Yield | 3.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Orion Office REIT (ONL) trades at $2.66, down 1.85% on the day, with a bearish technical outlook and mixed fundamentals. The company reported a Q2 2026 earnings beat but continues to post significant net losses, with a negative net income margin of -65.66% in 2025. Despite a low price-to-book ratio of 0.24, indicating potential undervaluation, declining revenues and negative profitability metrics highlight ongoing challenges in its office property portfolio.
The outlook remains cautious due to persistent operational losses and high debt levels, though analyst sentiment is split evenly between Buy and Hold. Key risks include further revenue erosion and interest expense pressures, while potential catalysts hinge on successful portfolio repositioning and stabilized office demand as highlighted in recent earnings calls.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
